verapamil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, verapamil derivatives 2815 52-53-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • verapamil
  • RS-Verapamil
  • (+/-)-Verapamil
  • verapamil hydrochloride
  • verapamil HCl
A calcium channel blocker that is a class IV anti-arrhythmia agent.
  • Molecular weight: 454.61
  • Formula: C27H38N2O4
  • CLOGP: 4.47
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 0
  • TPSA: 63.95
  • ALOGS: -5.06
  • ROTB: 13

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.24 g O
0.24 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.75 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.50 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 22 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.09 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 12, 1981 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 922.77 10.72 893 43044 145027 46497098
Bradycardia 427.57 10.72 411 43526 65887 46576238
Atrioventricular block complete 292.22 10.72 143 43794 7484 46634641
Hypotension 234.79 10.72 609 43328 231980 46410145
Toxicity to various agents 212.10 10.72 553 43384 211213 46430912
Cardiogenic shock 191.10 10.72 143 43794 16241 46625884
Drug interaction 166.31 10.72 493 43444 202601 46439524
Nodal rhythm 143.94 10.72 56 43881 1669 46640456
Metabolic acidosis 142.37 10.72 179 43758 38601 46603524
Atrioventricular block 123.38 10.72 78 43859 6733 46635392
Rheumatoid arthritis 108.81 10.72 45 43892 240170 46401955
Overdose 98.42 10.72 263 43674 101716 46540409
Intentional overdose 96.07 10.72 198 43739 64746 46577379
Nodal arrhythmia 90.85 10.72 37 43900 1246 46640879
Cardiac arrest 85.06 10.72 231 43706 90168 46551957
Sinus bradycardia 84.09 10.72 83 43854 13699 46628426
Atrioventricular block first degree 83.49 10.72 59 43878 6127 46635998
Acute respiratory distress syndrome 73.85 10.72 97 43840 21825 46620300
Atrial fibrillation 67.71 10.72 233 43704 103357 46538768
Anuria 66.34 10.72 67 43870 11364 46630761
Suicide attempt 58.24 10.72 147 43790 54889 46587236
Atrioventricular block second degree 57.78 10.72 39 43898 3760 46638365
Supraventricular tachycardia 53.10 10.72 64 43873 13206 46628919
Shock 50.67 10.72 81 43856 21764 46620361
Poisoning 50.38 10.72 64 43873 13930 46628195
Cardiac failure congestive 50.33 10.72 195 43742 91555 46550570
Electrocardiogram QT prolonged 50.10 10.72 133 43804 51192 46590933
Drug ineffective 43.78 10.72 418 43519 677420 45964705
Rhabdomyolysis 41.30 10.72 109 43828 41800 46600325
Vasoplegia syndrome 40.40 10.72 20 43917 1072 46641053
Joint swelling 39.92 10.72 59 43878 166014 46476111
Treatment failure 38.12 10.72 20 43917 93067 46549058
Arrhythmia 37.83 10.72 94 43843 34747 46607378
Rash 35.47 10.72 194 43743 356318 46285807
Myocardial stunning 35.38 10.72 11 43926 164 46641961
Cerebrovascular accident 35.33 10.72 188 43749 100851 46541274
Hyperglycaemia 34.33 10.72 91 43846 34980 46607145
Infusion related reaction 33.02 10.72 28 43909 101180 46540945
Contraindicated product administered 32.99 10.72 17 43920 79930 46562195
Hyperkalaemia 32.18 10.72 113 43824 50596 46591529
Labelled drug-drug interaction medication error 31.92 10.72 41 43896 9020 46633105
Electrocardiogram QRS complex prolonged 31.73 10.72 32 43905 5417 46636708
Circulatory collapse 30.86 10.72 65 43872 21559 46620566
Large intestine polyp 29.97 10.72 37 43900 7824 46634301
Drug intolerance 29.16 10.72 59 43878 146990 46495135
Non-cardiogenic pulmonary oedema 29.11 10.72 13 43924 551 46641574
Glossodynia 28.39 10.72 4 43933 44369 46597756
Systemic lupus erythematosus 28.20 10.72 13 43924 65167 46576958
Rhythm idioventricular 27.59 10.72 9 43928 158 46641967
Exposure during pregnancy 27.43 10.72 37 43900 108175 46533950
Ventricular extrasystoles 27.00 10.72 42 43895 11021 46631104
Off label use 26.23 10.72 230 43707 379611 46262514
Pulseless electrical activity 26.15 10.72 33 43904 7134 46634991
Pain 25.86 10.72 306 43631 476642 46165483
Cardio-respiratory arrest 25.61 10.72 118 43819 59751 46582374
Squamous cell carcinoma of the oral cavity 25.58 10.72 10 43927 302 46641823
Atrioventricular dissociation 24.96 10.72 9 43928 216 46641909
Alopecia 24.52 10.72 75 43862 162339 46479786
Bradyarrhythmia 24.48 10.72 18 43919 1988 46640137
Maternal exposure during pregnancy 24.08 10.72 37 43900 102512 46539613
Renal failure 23.98 10.72 186 43751 113408 46528717
Infection 23.69 10.72 57 43880 133535 46508590
Body temperature decreased 23.59 10.72 44 43893 13365 46628760
Pallor 23.58 10.72 61 43876 23105 46619020
Product coating issue 23.26 10.72 6 43931 43 46642082
Therapeutic product effect incomplete 22.70 10.72 24 43913 78129 46563996
Arthropathy 22.45 10.72 28 43909 84672 46557453
Hand deformity 22.40 10.72 3 43934 34571 46607554
Bundle branch block right 22.22 10.72 25 43912 4794 46637331
Poisoning deliberate 22.07 10.72 32 43905 7894 46634231
Arthralgia 21.27 10.72 230 43707 364373 46277752
Lower respiratory tract infection 20.88 10.72 13 43924 55076 46587049
Accidental overdose 20.59 10.72 53 43884 20013 46622112
Migraine 20.32 10.72 124 43813 69902 46572223
Suspected suicide 19.50 10.72 23 43914 4638 46637487
Therapeutic product effect decreased 19.20 10.72 30 43907 82571 46559554
Respiratory arrest 18.63 10.72 72 43865 33744 46608381
International normalised ratio increased 18.30 10.72 90 43847 46793 46595332
Ventricular fibrillation 18.11 10.72 36 43901 11460 46630665
Neutropenia 17.68 10.72 72 43865 143132 46498993
Blood phosphorus decreased 17.67 10.72 20 43917 3860 46638265
Gastric ulcer helicobacter 17.66 10.72 4 43933 15 46642110
Drug ineffective for unapproved indication 17.52 10.72 44 43893 16369 46625756
Miosis 17.27 10.72 26 43911 6631 46635494
Blood pressure immeasurable 17.25 10.72 12 43925 1215 46640910
Febrile neutropenia 17.07 10.72 40 43897 94587 46547538
Heart rate decreased 17.03 10.72 67 43870 31656 46610469
Lactic acidosis 16.91 10.72 70 43867 33839 46608286
Postresuscitation encephalopathy 16.90 10.72 4 43933 19 46642106
Melaena 16.85 10.72 61 43876 27711 46614414
Abdominal discomfort 16.84 10.72 79 43858 151086 46491039
Bundle branch block left 16.61 10.72 25 43912 6374 46635751
Mitral valve incompetence 16.54 10.72 47 43890 18805 46623320
Dizziness 16.47 10.72 428 43509 339986 46302139
Blood pressure decreased 15.82 10.72 100 43837 57059 46585066
Pulmonary oedema 15.79 10.72 92 43845 51013 46591112
Cardiotoxicity 15.69 10.72 25 43912 6697 46635428
Depressed level of consciousness 15.59 10.72 87 43850 47482 46594643
Pupillary reflex impaired 15.57 10.72 14 43923 2054 46640071
Medication error 15.57 10.72 64 43873 30847 46611278
Embolic stroke 15.30 10.72 18 43919 3621 46638504
Hepatic enzyme increased 15.21 10.72 34 43903 81753 46560372
Coma scale abnormal 15.10 10.72 21 43916 4985 46637140
Optic ischaemic neuropathy 14.92 10.72 10 43927 953 46641172
Gallbladder oedema 14.70 10.72 6 43931 203 46641922
Malignant neoplasm progression 14.69 10.72 24 43913 64902 46577223
Exfoliative rash 14.67 10.72 15 43922 2580 46639545
Prinzmetal angina 14.56 10.72 9 43928 746 46641379
Torsade de pointes 14.48 10.72 34 43903 12120 46630005
Acute kidney injury 14.29 10.72 306 43631 235549 46406576
Cardiac failure 14.24 10.72 126 43811 79822 46562303
Blood pressure inadequately controlled 14.07 10.72 19 43918 4387 46637738
Extrasystoles 14.06 10.72 20 43917 4849 46637276
Palpitations 13.93 10.72 144 43793 95115 46547010
Hyponatraemic syndrome 13.87 10.72 8 43929 584 46641541
Hypoperfusion 13.68 10.72 11 43926 1386 46640739
Pericarditis 13.48 10.72 3 43934 23924 46618201
Purpura senile 13.35 10.72 8 43929 627 46641498
Haemorrhage subcutaneous 13.27 10.72 15 43922 2891 46639234
Tarsal tunnel syndrome 13.12 10.72 8 43929 647 46641478
Coma 13.12 10.72 97 43840 58252 46583873
Electrocardiogram PR prolongation 13.08 10.72 8 43929 651 46641474
Peripheral swelling 13.08 10.72 91 43846 157980 46484145
Neutrophil count decreased 12.99 10.72 13 43924 43413 46598712
Sinus node dysfunction 12.95 10.72 18 43919 4271 46637854
Musculoskeletal stiffness 12.90 10.72 48 43889 97945 46544180
Loss of consciousness 12.82 10.72 157 43780 108081 46534044
Salivary gland calculus 12.63 10.72 5 43932 156 46641969
Pyrexia 12.57 10.72 242 43695 348560 46293565
Metastases to retroperitoneum 12.55 10.72 5 43932 159 46641966
Snake bite 12.39 10.72 3 43934 16 46642109
Respiratory depression 12.28 10.72 31 43906 11569 46630556
Electrocardiogram T wave abnormal 12.26 10.72 13 43924 2333 46639792
Product monitoring error 12.21 10.72 12 43925 1969 46640156
Ischaemic stroke 12.14 10.72 39 43898 16683 46625442
Periorbital oedema 12.13 10.72 19 43918 5016 46637109
Product use in unapproved indication 12.03 10.72 44 43893 90229 46551896
Abortion spontaneous 12.02 10.72 14 43923 43632 46598493
Chronic obstructive pulmonary disease 11.95 10.72 94 43843 57539 46584586
Coronary artery disease 11.92 10.72 63 43874 33689 46608436
Product used for unknown indication 11.88 10.72 7 43930 532 46641593
Fatigue 11.85 10.72 461 43476 608236 46033889
Ventricular tachyarrhythmia 11.78 10.72 4 43933 80 46642045
Diarrhoea 11.74 10.72 420 43517 559182 46082943
Cardiac septal hypertrophy 11.73 10.72 4 43933 81 46642044
Subendocardial ischaemia 11.55 10.72 4 43933 85 46642040
Ventricular hypertrophy 11.51 10.72 16 43921 3798 46638327
Cerebral infarction 11.47 10.72 48 43889 23318 46618807
Hospitalisation 11.26 10.72 27 43910 63358 46578767
Left ventricle outflow tract obstruction 10.87 10.72 5 43932 227 46641898
Cardioactive drug level decreased 10.87 10.72 4 43933 102 46642023
Product use issue 10.81 10.72 49 43888 94595 46547530

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 762.07 11.71 663 26202 98829 29826784
Bradycardia 265.46 11.71 310 26555 65216 29860397
Cardiogenic shock 256.90 11.71 170 26695 16691 29908922
Atrioventricular block complete 132.77 11.71 87 26778 8390 29917223
Toxicity to various agents 128.31 11.71 399 26466 176784 29748829
Shock 114.49 11.71 121 26744 22738 29902875
Intentional overdose 100.80 11.71 153 26712 41328 29884285
Hypotension 96.44 11.71 395 26470 200170 29725443
Overdose 73.34 11.71 203 26662 84134 29841479
Nodal rhythm 69.18 11.71 31 26834 1392 29924221
Drug interaction 56.97 11.71 339 26526 199229 29726384
Atrioventricular block first degree 55.93 11.71 44 26821 5644 29919969
Sinus bradycardia 53.44 11.71 59 26806 11636 29913977
Supraventricular tachycardia 52.52 11.71 55 26810 10217 29915396
Suicide attempt 50.98 11.71 106 26759 36591 29889022
Vasoplegia syndrome 44.27 11.71 22 26843 1249 29924364
Medication error 42.17 11.71 71 26794 20901 29904712
Cardiac arrest 41.42 11.71 179 26686 92671 29832942
Cerebral artery thrombosis 41.01 11.71 16 26849 505 29925108
Oesophageal ulcer haemorrhage 39.29 11.71 12 26853 177 29925436
Atrioventricular block 33.72 11.71 37 26828 7245 29918368
Lactic acidosis 32.04 11.71 80 26785 31133 29894480
Acute respiratory distress syndrome 31.66 11.71 67 26798 23405 29902208
Pyrexia 31.25 11.71 147 26718 294342 29631271
Brain scan abnormal 31.03 11.71 14 26851 639 29924974
Coma 30.89 11.71 93 26772 40356 29885257
Poisoning 30.51 11.71 44 26821 11338 29914275
Neutropenia 29.98 11.71 43 26822 128497 29797116
Sinoatrial block 28.98 11.71 12 26853 443 29925170
Arrhythmia 28.93 11.71 80 26785 33089 29892524
Hyperkalaemia 27.70 11.71 125 26740 65885 29859728
Febrile neutropenia 27.64 11.71 33 26832 106660 29818953
Normochromic normocytic anaemia 27.29 11.71 25 26840 3945 29921668
Prostatic adenoma 27.16 11.71 9 26856 175 29925438
Atrial fibrillation 26.59 11.71 177 26688 107947 29817666
Hemiplegia 26.03 11.71 31 26834 6630 29918983
Neuromyopathy 25.74 11.71 14 26851 958 29924655
Poisoning deliberate 25.62 11.71 29 26836 5875 29919738
Areflexia 24.53 11.71 20 26845 2699 29922914
Palpitations 24.51 11.71 76 26789 33497 29892116
Off label use 24.37 11.71 128 26737 249162 29676451
Diarrhoea 24.25 11.71 188 26677 333915 29591698
Pulse absent 23.95 11.71 27 26838 5446 29920167
Compartment syndrome 23.67 11.71 19 26846 2508 29923105
Rhythm idioventricular 23.37 11.71 9 26856 274 29925339
Pseudomonal sepsis 22.81 11.71 20 26845 2980 29922633
Anuria 22.18 11.71 36 26829 10280 29915333
Superinfection 21.52 11.71 15 26850 1599 29924014
Mallory-Weiss syndrome 21.24 11.71 14 26851 1362 29924251
Pneumonia 21.15 11.71 195 26670 334111 29591502
Neutrophil count decreased 21.01 11.71 6 26859 42448 29883165
Coma scale abnormal 20.79 11.71 20 26845 3356 29922257
Tobacco abuse 20.32 11.71 9 26856 393 29925220
Cluster headache 20.05 11.71 10 26855 572 29925041
Xanthelasma 19.25 11.71 6 26859 95 29925518
Pacemaker generated rhythm 19.14 11.71 5 26860 40 29925573
Nodal arrhythmia 19.04 11.71 11 26854 846 29924767
Non-cardiogenic pulmonary oedema 18.46 11.71 10 26855 679 29924934
Acute kidney injury 18.03 11.71 345 26520 273497 29652116
Fear of weight gain 17.85 11.71 4 26861 15 29925598
Pallor 17.60 11.71 50 26815 20999 29904614
Cardiorenal syndrome 17.44 11.71 10 26855 758 29924855
Infection 17.33 11.71 27 26838 78047 29847566
Cerebrovascular accident 17.21 11.71 131 26734 83346 29842267
Malignant neoplasm progression 17.02 11.71 24 26841 72263 29853350
Adrenal cortex necrosis 16.92 11.71 4 26861 20 29925593
Plasma cell myeloma 16.74 11.71 14 26851 53448 29872165
Rheumatoid arthritis 16.73 11.71 8 26857 41189 29884424
Cerebral haematoma 16 11.71 20 26845 4494 29921119
Ischaemic stroke 15.95 11.71 41 26824 16234 29909379
Drug ineffective 15.78 11.71 213 26652 340174 29585439
Pancytopenia 15.67 11.71 33 26832 85019 29840594
Disease progression 15.56 11.71 30 26835 79844 29845769
Antiacetylcholine receptor antibody positive 15.54 11.71 4 26861 30 29925583
Cardiac failure congestive 15.51 11.71 129 26736 84278 29841335
Benign prostatic hyperplasia 15.47 11.71 31 26834 10416 29915197
Pulmonary oedema 15.35 11.71 79 26786 43896 29881717
Metabolic acidosis 15.00 11.71 70 26795 37391 29888222
Prothrombin time ratio decreased 14.80 11.71 7 26858 356 29925257
Myofascial pain syndrome 14.75 11.71 7 26858 359 29925254
Hospitalisation 14.63 11.71 11 26854 44308 29881305
Atrioventricular block second degree 14.61 11.71 16 26849 3124 29922489
Acidosis 14.58 11.71 30 26835 10271 29915342
Erythromelalgia 13.85 11.71 4 26861 48 29925565
Lividity 13.84 11.71 5 26860 127 29925486
Extrasystoles 13.80 11.71 17 26848 3765 29921848
Bundle branch block left 13.77 11.71 20 26845 5184 29920429
Neck injury 13.73 11.71 10 26855 1142 29924471
Cerebral infarction 13.43 11.71 53 26812 26320 29899293
Gingival bleeding 13.29 11.71 22 26843 6382 29919231
Victim of crime 13.03 11.71 6 26859 287 29925326
Intensive care 12.97 11.71 6 26859 290 29925323
Lip discolouration 12.93 11.71 5 26860 154 29925459
Faecal calprotectin abnormal 12.49 11.71 5 26860 169 29925444
Treatment failure 12.25 11.71 8 26857 34671 29890942
Migraine 12.17 11.71 32 26833 12842 29912771
Carpal tunnel syndrome 12.13 11.71 17 26848 4266 29921347
Intentional product use issue 12.09 11.71 9 26856 36431 29889182
Thrombocytopenia 11.93 11.71 73 26792 136971 29788642
Atrial tachycardia 11.83 11.71 12 26853 2147 29923466
Bone marrow failure 11.76 11.71 6 26859 29779 29895834
Burns second degree 11.72 11.71 6 26859 363 29925250

Pharmacologic Action:

SourceCodeDescription
ATC C08DA01 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
Phenylalkylamine derivatives
ATC C08DA51 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
Phenylalkylamine derivatives
ATC C09BB10 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
FDA MoA N0000000069 Calcium Channel Antagonists
FDA EPC N0000175566 Calcium Channel Blocker
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35620 vasodilator
CHEBI has role CHEBI:35674 antihypertensive
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:38070 antiarrhythmic agent
CHEBI has role CHEBI:38215 calcium channel blockers
CHEBI has role CHEBI:62872 aldehyde oxidase (ec 1.2.3.1) inhibitors
CHEBI has role CHEBI:77255 lethal toxin inhibitor
CHEBI has role CHEBI:77745 meprin inhibitor
CHEBI has role CHEBI:77747 phospholipid-translocating atpase (ec 3.6.3.1) inhibitor
CHEBI has role CHEBI:77748 steroid-transporting atpase inhibitors
CHEBI has role CHEBI:78298 environmental contaminants
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Atrial fibrillation indication 49436004 DOID:0060224
Paroxysmal supraventricular tachycardia indication 67198005
Prinzmetal angina indication 87343002
Angina pectoris indication 194828000
Acute coronary syndrome indication 394659003
Prevention of Paroxysmal Supraventricular Tachycardia indication
Cardioversion of Atrial Fibrillation indication
Diastolic heart failure off-label use 418304008 DOID:9775
Cluster Headache Prevention off-label use
Hyperkalemia contraindication 14140009
Ventricular tachycardia contraindication 25569003
Complete atrioventricular block contraindication 27885002
Acute cerebrovascular insufficiency contraindication 29322000
Sick sinus syndrome contraindication 36083008 DOID:13884
Immunosuppression contraindication 38013005
Angioedema contraindication 41291007 DOID:1558
Low cardiac output syndrome contraindication 44088000
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Lown-Ganong-Levine syndrome contraindication 55475008 DOID:13087
Aortic valve stenosis contraindication 60573004 DOID:1712
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Duchenne muscular dystrophy contraindication 76670001 DOID:11723
Transplantation contraindication 77465005
Chronic idiopathic constipation contraindication 82934008
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Left heart failure contraindication 85232009
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of connective tissue contraindication 105969002 DOID:65
Liver function tests abnormal contraindication 166603001
Second degree atrioventricular block contraindication 195042002
Hypertrophic cardiomyopathy contraindication 233873004 DOID:11984
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
First Degree Atrioventricular Heart Block contraindication
Neuromuscular Transmission Deficiency contraindication
Hemodialysis with High-Flux Membrane contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.91 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent L-type calcium channel subunit alpha-1S Ion channel BLOCKER UNKNOWN IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel BLOCKER IC50 6 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 6.85 PDSP
Alpha-2A adrenergic receptor GPCR Ki 6.66 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.90 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.76 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.98 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.81 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 7.20 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.59 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 6.07 DRUG MATRIX
Potassium voltage-gated channel subfamily C member 2 Ion channel EC50 4.90 WOMBAT-PK
Aldehyde oxidase Enzyme IC50 5.46 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 4.07 WOMBAT-PK
Potassium voltage-gated channel subfamily A member 7 Ion channel Kd 4.80 WOMBAT-PK
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Ion channel IC50 4.35 WOMBAT-PK
Potassium voltage-gated channel subfamily A member 10 Ion channel BLOCKER IC50 4.30 IUPHAR
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel BLOCKER Ki 4.49 WOMBAT-PK
Carbonic anhydrase 1 Enzyme WOMBAT-PK
Sodium channel protein type 5 subunit alpha Ion channel WOMBAT-PK
G protein-activated inward rectifier potassium channel 2 Ion channel WOMBAT-PK
Equilibrative nucleoside transporter 4 Transporter INHIBITOR Ki 4.73 IUPHAR
Multidrug resistance protein 1 Transporter Ki 6.52 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 5.17 CHEMBL
Multidrug resistance-associated protein 1 Transporter Ki 4.88 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 8 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.48 CHEMBL
Potassium voltage-gated channel subfamily A member 3 Ion channel IC50 5.10 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter EC50 4.43 CHEMBL
Cytochrome P450 3A4 Enzyme INHIBITOR Ki 6.22 IUPHAR
Two pore calcium channel protein 2 Unclassified BLOCKER IC50 5 IUPHAR
Two pore calcium channel protein 1 Unclassified BLOCKER IC50 4.64 IUPHAR
Alpha-1B adrenergic receptor GPCR Ki 6.03 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.76 DRUG MATRIX
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel IC50 6 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1S Ion channel Ki 7.24 CHEMBL
Translocator protein Membrane receptor IC50 8.85 CHEMBL
Chloroquine resistance transporter Unclassified IC50 4.52 CHEMBL
Voltage-gated L-type calcium channel Ion channel IC50 8.43 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel IC50 7.41 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR EC50 4.51 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.52 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 5.68 CHEMBL
Potassium voltage-gated channel subfamily C member 2 Unclassified BLOCKER EC50 4.90 IUPHAR

External reference:

IDSource
4019969 VUID
N0000148054 NUI
D00619 KEGG_DRUG
152-11-4 SECONDARY_CAS_RN
4018128 VANDF
4019969 VANDF
C0042523 UMLSCUI
CHEBI:9948 CHEBI
2520 PUBCHEM_CID
CHEMBL6966 ChEMBL_ID
CHEMBL1280 ChEMBL_ID
D014700 MESH_DESCRIPTOR_UI
2122 INN_ID
DB00661 DRUGBANK_ID
CJ0O37KU29 UNII
2406 IUPHAR_LIGAND_ID
11170 RXNORM
5670 MMSL
757 MMSL
d00048 MMSL
000709 NDDF
004515 NDDF
14340003 SNOMEDCT_US
372754009 SNOMEDCT_US
47898004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-1891 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL NDA 23 sections
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-1901 TABLET, FILM COATED, EXTENDED RELEASE 120 mg ORAL NDA 23 sections
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-1911 TABLET, FILM COATED, EXTENDED RELEASE 180 mg ORAL NDA 23 sections
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-2712 TABLET, FILM COATED, EXTENDED RELEASE 120 mg ORAL NDA 23 sections
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-2818 TABLET, FILM COATED, EXTENDED RELEASE 180 mg ORAL NDA 23 sections
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-2924 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL NDA 23 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 0074-3287 TABLET, FILM COATED, EXTENDED RELEASE 180 mg ORAL NDA 20 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 0074-3288 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL NDA 20 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 0074-3289 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL NDA 20 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 0074-3290 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL NDA 20 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6320 CAPSULE, EXTENDED RELEASE 120 mg ORAL ANDA 16 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6380 CAPSULE, EXTENDED RELEASE 180 mg ORAL ANDA 16 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6440 CAPSULE, EXTENDED RELEASE 240 mg ORAL ANDA 16 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1144 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 17 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1144 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 17 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-4011 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 17 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-9633 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 17 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0343 TABLET, FILM COATED 80 mg ORAL ANDA 20 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0345 TABLET, FILM COATED 120 mg ORAL ANDA 20 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0404 TABLET, FILM COATED 40 mg ORAL ANDA 20 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2880 CAPSULE, DELAYED RELEASE PELLETS 120 mg ORAL NDA 24 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2882 CAPSULE, DELAYED RELEASE PELLETS 180 mg ORAL NDA 24 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2884 CAPSULE, DELAYED RELEASE PELLETS 240 mg ORAL NDA 24 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2886 CAPSULE, DELAYED RELEASE PELLETS 360 mg ORAL NDA 24 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-3588 TABLET, FILM COATED, EXTENDED RELEASE 180 mg ORAL ANDA 23 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-3589 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL ANDA 23 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7618 TABLET, FILM COATED 80 mg ORAL ANDA 19 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7619 TABLET, FILM COATED 120 mg ORAL ANDA 19 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-2920 TABLET, FILM COATED 80 mg ORAL ANDA 20 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-2924 TABLET, FILM COATED 120 mg ORAL ANDA 20 sections